Aplagon
Develops therapies for patients with thromboinflammatory cardiovascular diseases
Highlights
- New on EvolcAdded 2026-10-28
About Aplagon
Aplagon is a clinical-stage biopharmaceutical company developing therapies for thromboinflammatory diseases. Its lead asset, APAC, is a heparin proteoglycan mimetic designed to act as an antiplatelet, anticoagulant and anti-inflammatory treatment.
APAC is in clinical studies for two cardiovascular indications. The company is backed by Finnish investors and has announced financing to broaden its Phase 2 trials.
Founded in 2009, Aplagon is headquartered in Helsinki, where it has offices and a laboratory.
Product: APAC, an investigational heparin proteoglycan mimetic for thromboinflammatory diseases.
Jobs at Aplagon
Leadership
- Sakari Lassila · Non-Executive Director, Co-founder; M.Sc. (Econ. and BA)Source: company website
More biotech & pharma companies
Aq Biotech
Develops phage-based biosensor diagnostics for early disease detection and monitoring from non-invasive biological samplesYoung companyNew on EvolcAranda Pharma
Develops drug candidates for people with hair loss, acne and brain diseasesNew on EvolcAurealis
Develops bacterial gene therapies for patients with chronic wounds, cancer and inflammatory diseasesNew on EvolcAurlide
Drug discovery services for pharma teams: virtual screening for first hits, hit-to-lead optimization and pharmacokinetics toolsNew on EvolcAvenue Biosciences
Signal peptide engineering with machine learning to raise protein production yields for biologics developersYoung companyRemote-friendlyBioGenium Microsystems
Biomimicking cell culture devices and organ-on-chip systems for researchers in drug development and cancer studiesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Google Analytics 4
- WordPress
- jQuery
- nginx